Login / Signup

Good efficacy and safety of vedolizumab in Crohn's disease and ulcerative colitis in a real-world scenario.

Fabiana ZingoneBrigida BarberioFederico CompostellaGiulia GirardinRenata D'IncàCarla MarinelliIlaria MarsilioGreta LorenzonEdoardo Vincenzo Savarino
Published in: Therapeutic advances in gastroenterology (2020)
Vedolizumab resulted in being effective and safe in CD as well as in UC patients.
Keyphrases
  • ulcerative colitis
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • patient reported